PXS vs. ALK, SHIP, TORO, CLCO, ICON, PAA, GEL, MMP, AAL, and CCL
Should you be buying Provexis stock or one of its competitors? The main competitors of Provexis include Alkemy Capital Investments (ALK), Tufton Oceanic Assets (SHIP), Chenavari Toro Income Fund (TORO), CloudCoCo Group (CLCO), Iconic Labs (ICON), 22532 (PAA.L) (PAA), Greka Engineering & Technology (GEL), Marwyn Management Partners (MMP), Anglo American (AAL), and Carnival Co. & (CCL). These companies are all part of the "transportation" industry.
Provexis vs.
Provexis (LON:PXS) and Alkemy Capital Investments (LON:ALK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, community ranking, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.
Alkemy Capital Investments has a net margin of 0.00% compared to Provexis' net margin of -73.10%. Alkemy Capital Investments' return on equity of 181.08% beat Provexis' return on equity.
7.9% of Provexis shares are held by institutional investors. Comparatively, 1.5% of Alkemy Capital Investments shares are held by institutional investors. 21.6% of Provexis shares are held by insiders. Comparatively, 43.7% of Alkemy Capital Investments shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Provexis has higher revenue and earnings than Alkemy Capital Investments. Provexis is trading at a lower price-to-earnings ratio than Alkemy Capital Investments, indicating that it is currently the more affordable of the two stocks.
In the previous week, Alkemy Capital Investments had 3 more articles in the media than Provexis. MarketBeat recorded 3 mentions for Alkemy Capital Investments and 0 mentions for Provexis. Alkemy Capital Investments' average media sentiment score of 0.66 beat Provexis' score of 0.00 indicating that Alkemy Capital Investments is being referred to more favorably in the news media.
Alkemy Capital Investments received 92 more outperform votes than Provexis when rated by MarketBeat users. Likewise, 76.88% of users gave Alkemy Capital Investments an outperform vote while only 64.21% of users gave Provexis an outperform vote.
Provexis has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Alkemy Capital Investments has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500.
Summary
Alkemy Capital Investments beats Provexis on 9 of the 14 factors compared between the two stocks.
Get Provexis News Delivered to You Automatically
Sign up to receive the latest news and ratings for PXS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Provexis Competitors List
Related Companies and Tools
This page (LON:PXS) was last updated on 2/22/2025 by MarketBeat.com Staff
Free PXS Stock Alerts